JP2014141531A - Completion version of cancer eradication oral medicine - Google Patents

Completion version of cancer eradication oral medicine Download PDF

Info

Publication number
JP2014141531A
JP2014141531A JP2014098205A JP2014098205A JP2014141531A JP 2014141531 A JP2014141531 A JP 2014141531A JP 2014098205 A JP2014098205 A JP 2014098205A JP 2014098205 A JP2014098205 A JP 2014098205A JP 2014141531 A JP2014141531 A JP 2014141531A
Authority
JP
Japan
Prior art keywords
cancer
mir
oral medicine
micrornas
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014098205A
Other languages
Japanese (ja)
Inventor
Isao Kajisa
功 加治佐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2014098205A priority Critical patent/JP2014141531A/en
Publication of JP2014141531A publication Critical patent/JP2014141531A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide the completion version of a cancer eradication oral medicine.SOLUTION: A completion version of cancer eradication oral medicine is characterized by preparation of miR-520d which is one of microRNAs required for initializing a cancer cell mainly by a human iPS mediation, and by simplification from a conventional miR-520d venous injection to oral ingestion by coating or encapsulation to protect from gastric acid or heat. Thus, the miR-520d, which is one of the microRNAs, is digested and absorbed in intestine, and spreads hematogenously throughout the body, and completed by initializing all cells of systemic terminal cancer and returning to normal cells.

Description

本発明は、ヒトｉＰＳを介したがんの完治を目的とした治療薬に関する。 The present invention relates to a therapeutic agent aimed at complete cure of cancer via human iPS.

従来、ヒトｉＰＳがん初期化の発見発明があったが全身がん細胞まで届ける技術はなかった。  Conventionally, there has been a discovery invention of human iPS cancer reprogramming, but there has been no technology for delivering systemic cancer cells.

「ニュートン」2014年4月号、9頁。“Newton” April 2014 issue, page 9. 「日経プレスリリース」2014年1月25日。“Nikkei Press Release” January 25, 2014. 「サイエンティフィクレポート誌オンライン版」2014年1月24日付“Scientific Report Magazine Online” dated January 24, 2014 特開2011-142833JP2011-142833

従来、ヒトｉＰＳがん初期化の発見発明があったが全身がん細胞まで届ける技術はなかったので最新技術よって改良実現させる。   Conventionally, there has been a discovery invention for human iPS cancer reprogramming, but there has been no technology for delivering systemic cancer cells, so improvements are realized by the latest technology.

ヒトｉＰＳ仲介がん細胞初期化するmiR-520dをカプセルに入れるかコーティングして経口で腸での消化吸収し血液成分として全身のがん細胞まで届ける。   Encapsulate or coat miR-520d, which initializes human iPS-mediated cancer cells, and digestively absorb in the intestine and deliver it to cancer cells throughout the body as a blood component.

全身がん細胞を正常細胞に初期化して治す。   Initialize and cure systemic cancer cells to normal cells.

以下、本発明の実施例について時系列的に文章で説明する。主としてヒトｉＰＳ仲介でがん細胞を初期化するのに必要なマイクロＲＮAの1つであるmiR-520dを用意し、これを胃酸や熱で壊れないようにコーティングするか、カプセルに入れ、従来、miR-520dを血液中に入れていたが、これを経口式にすることで口から飲むという単純化とし、このようにしてマイクロＲＮAの1つであるmiR-520dを腸で消化吸収し血液中の成分となり全身に血液に乗って行き渡り全身末期がんの全細胞が初期化し正常細胞に戻りで完成する、
以上のような特徴を持つ完成版がん根絶経口薬。 Hereinafter, embodiments of the present invention will be described in a chronological order in text. Prepare miR-520d, which is one of the microRNAs necessary for reprogramming cancer cells mainly mediated by human iPS, and either coat it with gastric acid or heat so that it does not break or encapsulate it. miR-520d was put in the blood, but by making it oral, it was simplified to drink from the mouth, and miR-520d, one of the microRNAs, was digested and absorbed in the intestine in this way. It becomes a component of and spreads on blood throughout the body, completes all cells of end-stage cancer and returns to normal cells to complete.
Completed cancer eradication oral medicine with the above characteristics.

上記の形態や非特許文献の如く実施される。 The present invention is implemented as in the above forms and non-patent documents.

従来、ヒトｉＰＳがん初期化の発見発明があったが全身がん細胞まで届ける技術はなかったので最新技術よって改良実現させるため、ヒトｉＰＳ仲介がん細胞初期化するmiR-520dをカプセルに入れるかコーティングして経口で腸での消化吸収し血液成分として全身のがん細胞まで届ける。 がん薬の改良技術で大きく進歩を遂げがん患者数が多い中この薬の需要の産業上の利用可能性は高いと解される。

Previously, there was a discovery invention of human iPS cancer reprogramming, but there was no technology to reach whole body cancer cells, so miR-520d for human iPS-mediated cancer cell reprogramming is encapsulated in order to improve it with the latest technology Or it is coated and digested and absorbed in the intestine and delivered to cancer cells throughout the body as a blood component. While significant progress has been made in improving cancer drugs and the number of cancer patients is large, it is understood that the industrial applicability of this drug demand is high.

Claims (1)

（ィ）主としてヒトｉＰＳ仲介でがん細胞を初期化するのに必要なマイクロＲＮAの1つであるmiR-520dを用意し、
（ロ）これを胃酸や熱で壊れないようにコーティングするか、カプセルに入れ、
（ハ）従来、miR-520dを血液中に入れていたが、これを経口式にすることで口から飲むという単純化とし、
（ニ）このようにしてマイクロＲＮAの1つであるmiR-520dを腸で消化吸収し血液中の成分となり全身に血液に乗って行き渡り全身末期がんの全細胞が初期化し正常細胞に戻りで完成する、
以上のような特徴を持つ完成版がん根絶経口薬。

(I) Prepare miR-520d, which is one of the microRNAs required to reprogram cancer cells mainly mediated by human iPS,
(B) Coat this so that it is not broken by stomach acid or heat, or put it in a capsule,
(C) Traditionally miR-520d was put in the blood, but by making it oral, it was simplified to drink from the mouth,
(D) In this way, miR-520d, one of the microRNAs, is digested and absorbed in the intestine, becomes a component in the blood, rides on the whole body and spreads throughout the body, and all cells of the end-stage cancer are initialized and returned to normal cells. Complete,
Completed cancer eradication oral medicine with the above characteristics.

JP2014098205A 2014-05-10 2014-05-10 Completion version of cancer eradication oral medicine Pending JP2014141531A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014098205A JP2014141531A (en) 2014-05-10 2014-05-10 Completion version of cancer eradication oral medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014098205A JP2014141531A (en) 2014-05-10 2014-05-10 Completion version of cancer eradication oral medicine

Publications (1)

Publication Number Publication Date
JP2014141531A true JP2014141531A (en) 2014-08-07

Family

ID=51423108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014098205A Pending JP2014141531A (en) 2014-05-10 2014-05-10 Completion version of cancer eradication oral medicine

Country Status (1)

Country Link
JP (1) JP2014141531A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535045A (en) * 2006-05-04 2009-10-01 ノバルティス アクチエンゲゼルシャフト Small interfering ribonucleic acid (siRNA) for oral administration
JP2010053078A (en) * 2008-08-28 2010-03-11 Teika Seiyaku Kk Percutaneously absorbable pharmaceutical composition of oxycodone, pharmaceutical composition storage unit and percutaneously absorbable preparation by utilizing the same
WO2012081531A1 (en) * 2010-12-14 2012-06-21 新田ゼラチン株式会社 Disease inhibiting agent
JP2013147459A (en) * 2012-01-19 2013-08-01 Mikasa Seiyaku Co Ltd Pruritus improvement percutaneous absorption plaster
JP2013189451A (en) * 2007-03-02 2013-09-26 Teika Seiyaku Kk Medicinal composition storing unit
JP2014037358A (en) * 2012-08-13 2014-02-27 Osaka Univ Oral formulation of nucleic acid medicine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535045A (en) * 2006-05-04 2009-10-01 ノバルティス アクチエンゲゼルシャフト Small interfering ribonucleic acid (siRNA) for oral administration
JP2013189451A (en) * 2007-03-02 2013-09-26 Teika Seiyaku Kk Medicinal composition storing unit
JP2010053078A (en) * 2008-08-28 2010-03-11 Teika Seiyaku Kk Percutaneously absorbable pharmaceutical composition of oxycodone, pharmaceutical composition storage unit and percutaneously absorbable preparation by utilizing the same
WO2012081531A1 (en) * 2010-12-14 2012-06-21 新田ゼラチン株式会社 Disease inhibiting agent
JP2013147459A (en) * 2012-01-19 2013-08-01 Mikasa Seiyaku Co Ltd Pruritus improvement percutaneous absorption plaster
JP2014037358A (en) * 2012-08-13 2014-02-27 Osaka Univ Oral formulation of nucleic acid medicine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015016294; Ｓｃｉｅｎｔｉｆｉｃ　Ｒｅｐｏｒｔｓ，　２０１４．１，　ｖｏｌ．４，　Ｎｏ．３８５２，　Ｎｏ．１-１４ *

Similar Documents

Publication Publication Date Title
BR212016030926U2 (en) target conjugates and particles and formulations thereof
WO2017091749A8 (en) Shape changing drug delivery devices and methods
WO2016046793A3 (en) Radiopharmaceutical conjugate of a metabolite and an epr agent, for targeting tumour cells
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
EP4233978A3 (en) Oral delivery of active drug substances
EA201791702A1 (en) THERAPEUTIC TOOLS ON THE BASIS OF GLYCANS AND RELATED METHODS
JP2011079858A5 (en)
EA201491299A1 (en) CARBAMATIC CONNECTIONS, THEIR PRODUCTION AND APPLICATION
EA201690207A1 (en) TRADITIONAL CHINESE MEDICINE COMPOSITION AND DRUGS AND THEIR APPLICATION
JP2016532516A5 (en)
MX367597B (en) Silk-based capsules.
BR112017028552A2 (en) particles and conjugates and formulations thereof
WO2016040462A3 (en) Formulations and methods for treatment of metabolic syndrome
JP2014141531A (en) Completion version of cancer eradication oral medicine
MX2017002897A (en) Semi-solid chewable dosage form for over-the-counter medications and methods for producing same.
JP2015044878A5 (en)
JP2014506563A5 (en)
CN104547150A (en) Application of inflammation-diminishing and pain-relieving external medicine as oral agent for treating tumors and ulcerative carbuncles
Fang et al. Shall CRT-D be downgraded to CRT-P in super-responders of cardiac resynchronization therapy?
JP2016533856A5 (en)
Sharma et al. C58 EMERGING TECHNIQUES AND NEW TOOLS TO UNDERSTAND LUNG DISEASES: Lung Targeted Plga-Peg Nanocapsules Containing First Line Anti-Tubercular Drugs For Therapy Of Experimental Tuberculosis
PH12014502170A1 (en) Drug composition and soft capsule drug sealing the drug composition
Menéndez et al. Diagnosis and therapy of Hepatocarcinoma: update of the topic and the internist s role
CN103585217A (en) Setose thistle/herba cephalanoploris pill
CN103585487A (en) Reed rhizome/couch-grass root pill

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150512

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151013